您的当前位置：首页 > 行业数据 > Figure 4： Baseline sBCMA (A), E：T ratioa (B), CD4+ TN at apheresisb (C), and CD4+ TEM at achievement of MRD negative ≥CR at month 12

Figure 4： Baseline sBCMA (A), E：T ratioa (B), CD4+ TN at apheresisb (C), and CD4+ TEM at achievement of MRD negative ≥CR at month 12

行业数据

下载图片

原图定位

同报告图片

/ 4

Figure 4： Baseline sBCMA (A), E：T ratioa (B), CD4+ TN at apheresisb (C), and CD4+ TEM at achievement of MRD negative ≥CR at month 12_第1页

Figure 4： Baseline sBCMA (A), E：T ratioa (B), CD4+ TN at apheresisb (C), and CD4+ TEM at achievement of MRD negative ≥CR at month 12_第2页

Figure 4： Baseline sBCMA (A), E：T ratioa (B), CD4+ TN at apheresisb (C), and CD4+ TEM at achievement of MRD negative ≥CR at month 12_第3页

Figure 4： Baseline sBCMA (A), E：T ratioa (B), CD4+ TN at apheresisb (C), and CD4+ TEM at achievement of MRD negative ≥CR at month 12_第4页

Figure 4： Baseline sBCMA (A), E：T ratioa (B), CD4+ TN at apheresisb (C), and CD4+ TEM at achievement of MRD negative ≥CR at month 12_第5页

所属报告：

传奇生物Legend Biotech（LEGN）2025年20-F年度报告「NASDAQ」（英文版）（720页）.pdf

打包全文图表

全行业研究报告分享下载平台

0731-84720580
商务合作：really158d

关于我们

网站声明
免责声明
网站公告
我要入驻

常见问题
用户协议
认证协议
版权申诉

关于我们

三个皮匠报告微信公众号

三个皮匠报告微信小程序

扫码咨询网站充值下载问题

客服

商务合作

小程序

服务号

折叠

Figure 4： Baseline sBCMA (A), E：T ratioa (B), CD4+ TN at apheresisb (C), and CD4+ TEM at achievement of MRD negative ≥CR at month 12

相关数据

最新数据